Cargando…

A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain

GNF-2 is an allosteric inhibitor of Bcr-Abl. It was developed as a new class of anti-cancer drug to treat resistant chronic myelogenous leukemia. Recent studies suggest that c-Abl inhibition would provide a neuroprotective effect in animal models of Parkinson’s disease as well as in clinical trials....

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Gyun Jee, Rahman, Md Habibur, Jha, Mithilesh Kumar, Gupta, Deepak Prasad, Park, Sung Hee, Kim, Jae-Hong, Lee, Sun-Hwa, Lee, In-Kyu, Sim, Taebo, Bae, Yong Chul, Lee, Won-Ha, Suk, Kyoungho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535676/ https://www.ncbi.nlm.nih.gov/pubmed/31164822 http://dx.doi.org/10.3389/fphar.2019.00543

Ejemplares similares

Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism
por: Khateb, Mamduh, et al.
Publicado: (2012)

Glia as a Link between Neuroinflammation and Neuropathic Pain
por: Jha, Mithilesh Kumar, et al.
Publicado: (2012)

A multiplexed siRNA screen identifies key kinase signaling networks of brain glia
por: Kim, Jong-Heon, et al.
Publicado: (2023)

Astrocytic pyruvate dehydrogenase kinase-2 is involved in hypothalamic inflammation in mouse models of diabetes
por: Rahman, Md Habibur, et al.
Publicado: (2020)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

Metabolic Regulation of Glial Phenotypes: Implications in Neuron–Glia Interactions and Neurological Disorders
por: Afridi, Ruqayya, et al.
Publicado: (2020)

Role of Hippocampal Lipocalin-2 in Experimental Diabetic Encephalopathy
por: Bhusal, Anup, et al.
Publicado: (2019)

Corrigendum: Role of Hippocampal Lipocalin-2 in Experimental Diabetic Encephalopathy
por: Bhusal, Anup, et al.
Publicado: (2019)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Pyruvate Dehydrogenase Kinase as a Potential Therapeutic Target for Malignant Gliomas
por: Jha, Mithilesh Kumar, et al.
Publicado: (2013)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms
por: Yang, Naery, et al.
Publicado: (2018)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Corrigendum: Interglial Crosstalk in Obesity-Induced Hypothalamic Inflammation
por: Rahman, Md Habibur, et al.
Publicado: (2019)

Interglial Crosstalk in Obesity-Induced Hypothalamic Inflammation
por: Rahman, Md Habibur, et al.
Publicado: (2018)

Lactate Transporters Mediate Glia-Neuron Metabolic Crosstalk in Homeostasis and Disease
por: Jha, Mithilesh Kumar, et al.
Publicado: (2020)

Pyruvate Dehydrogenase Kinases in the Nervous System: Their Principal Functions in Neuronal-glial Metabolic Interaction and Neuro-metabolic Disorders
por: Jha, Mithilesh Kumar, et al.
Publicado: (2012)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Acute Phase Protein Lipocalin-2 Is Associated with Formalin-induced Nociception and Pathological Pain
por: Jha, Mithilesh Kumar, et al.
Publicado: (2013)

Mitochondrial Dynamics and Bioenergetic Alteration During Inflammatory Activation of Astrocytes
por: Rahman, Md Habibur, et al.
Publicado: (2020)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Imatinib and GNF-5 Exhibit an Inhibitory Effect on Growth of Hepatocellar Carcinoma Cells by Downregulating S-phase Kinase-associated Protein 2
por: Zhang, Haibo, et al.
Publicado: (2020)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis
por: Baum, Karina J, et al.
Publicado: (2008)

Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus
por: Huang, Zheng-Lan, et al.
Publicado: (2013)

IGF-IR determines the fates of BCR/ABL leukemia
por: Xie, Jingjing, et al.
Publicado: (2015)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
por: Kim, Jaeseung C., et al.
Publicado: (2023)

The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome-Positive Acute Lymphatic Leukemia
por: Rafiei, Anahita, et al.
Publicado: (2015)

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022)

A novel role for protein tyrosine phosphatase 1B as a positive regulator of neuroinflammation
por: Song, Gyun Jee, et al.
Publicado: (2016)

Chemogenetic stimulation of the G(i) pathway in astrocytes suppresses neuroinflammation
por: Kim, Jae‐Hong, et al.
Publicado: (2021)

Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia
por: Kim, Yeojae, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rtmhejd9i1lrimo3n8t5401c7n